# **Special Issue**

# Mechanisms of Cancer Cells Escape from Immune Surveillance: The Focus on Epigenetic and Proinflammatory Adaptations

### Message from the Guest Editors

Anti-cancer surveillance is one of the most important functions of the immune system as it helps to eliminate transformed and malfunctioning cells. However, many cancer cells manage to hide from the screening for elimination and/or survive the immune defense mechanisms. Cancer cell survival results in the development of resistance, metastasis, and cancer recurrence. This Special Issue of Cancers presents current advances in the understanding of molecular mechanisms of cancer cell escape from immune surveillance and development of cancer chemo- and radio-resistance. Also focuses on the description of novel anticancer methodologies that target epigenetic gene regulation and the pro-inflammatory tumor microenvironment. Original research manuscripts, insightful reviews, and idea-provoking letters that discuss novel mechanisms of cancer cells' adaptations to immune surveillance, survival, and resistance are invited.

### **Guest Editors**

Dr. Olga Sukocheva

College of Nursing and Health Sciences, Flinders Medical Centre, Flinders University, Adelaide 5001, Australia

### Dr. Margarita Neganova

Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Severnii pr-d 1, Chernogolovka 142432, Russia

### Deadline for manuscript submissions

closed (30 September 2024)



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/175988

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

